A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy.

COVID-19 Italy SARS-CoV-2 variants SEIR model model calibration vaccines

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
17 Aug 2021
Historique:
received: 25 06 2021
revised: 29 07 2021
accepted: 12 08 2021
entrez: 28 8 2021
pubmed: 29 8 2021
medline: 29 8 2021
Statut: epublish

Résumé

From the end of 2020, different vaccines against COVID-19 have been approved, offering a glimmer of hope and relief worldwide. However, in late 2020, new cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started to re-surge, worsened by the emergence of highly infectious variants. To study this scenario, we extend the Susceptible-Exposed-Infectious-Removed model with lockdown measures used in our previous work with the inclusion of new lineages and mass vaccination campaign. We estimate model parameters using the Bayesian method Conditional Robust Calibration in two case studies: Italy and the Umbria region, the Italian region being worse affected by the emergence of variants. We then use the model to explore the dynamics of COVID-19, given different vaccination paces and a policy of gradual reopening. Our findings confirm the higher reproduction number of Umbria and the increase of transmission parameters due to the presence of new variants. The results illustrate the importance of preserving population-wide interventions, especially during the beginning of vaccination. Finally, under the hypothesis of waning immunity, the predictions show that a seasonal vaccination with a constant rate would probably be necessary to control the epidemic.

Identifiants

pubmed: 34452040
pii: vaccines9080915
doi: 10.3390/vaccines9080915
pmc: PMC8402493
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Environ Res. 2021 Jun;197:111097
pubmed: 33811866
Science. 2020 Aug 14;369(6505):846-849
pubmed: 32576668
BMC Syst Biol. 2009 May 11;3:51
pubmed: 19432996
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
IET Syst Biol. 2020 Jun;14(3):107-119
pubmed: 32406375
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
Science. 2020 Nov 13;370(6518):811-818
pubmed: 32958581
Euro Surveill. 2021 Jun;26(25):
pubmed: 34169819
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Results Phys. 2021 Feb;21:103746
pubmed: 33391984
Lancet Infect Dis. 2021 Jun;21(6):793-802
pubmed: 33743847
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Nat Med. 2021 Jun;27(6):993-998
pubmed: 33864052
Biology (Basel). 2020 Nov 11;9(11):
pubmed: 33187109
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Nature. 2021 Jan 14;:
pubmed: 33441993
Viruses. 2021 Apr 29;13(5):
pubmed: 33946747

Auteurs

Chiara Antonini (C)

ICT4life Srl, Via Mario Donati Guerrieri, 16, 06132 Perugia, Italy.

Sara Calandrini (S)

ICT4life Srl, Via Mario Donati Guerrieri, 16, 06132 Perugia, Italy.
Department of Engineering, University of Perugia, Via Goffredo Duranti, 93, 06125 Perugia, Italy.

Fortunato Bianconi (F)

COVID-19 Epidemiological Unit, Regional Government of Umbria, Corso Vannucci, 96, 06121 Perugia, Italy.

Classifications MeSH